Top of the Street: Demant, Sonova, Bayer, Deutsche Boerse
11/06/2025 14:15
A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Exane BNP Paribas raises Danish hearing solutions company Demant DEMANT.CO to "outperform" from "neutral" as it says the company's new product cycle in H2 will end a two-year EPS downgrade ** It cuts Sonova SOON.S to "underperform" from "outperform", saying it is weighed down by slowing positive effects from the company's latest product launch and competitive pressure ** HSBC upgrades Bayer BAYGn.DE to "buy" from "hold", saying litigation resolution is in sight, de-gearing the balance sheet is a possible next step and Asundexian may be a positive for sales from Q4 2025 for the German pharmaceutical group ** UBS cuts Deutsche Boerse DB1Gn.DE to "neutral" from "buy" as it says the German stock exchange group's valuation has reached its peak and expects "trading fatigue" to mean limited upside (*Analyst rankings from Thomson Reuters StarMine. The scale is from 1-star to 5-star with 5 being the best. Analysts are ranked on earnings accuracy as well as relative performance of recommendations over trailing 12-month & 24-month periods.) (Reporting by Bernadette Hogg and Agnieszka Oleńska; Editing by Vijay Kishore) ((bernadette.hogg@thomsonreuters.com))